Walter M. Stadler to Follow-Up Studies
This is a "connection" page, showing publications Walter M. Stadler has written about Follow-Up Studies.
Connection Strength
0.346
-
Phase III study of molecularly targeted adjuvant therapy in locally advanced urothelial cancer of the bladder based on p53 status. J Clin Oncol. 2011 Sep 01; 29(25):3443-9.
Score: 0.059
-
Prognostic factors for survival with gemcitabine plus 5-fluorouracil based regimens for metastatic renal cancer. J Urol. 2003 Oct; 170(4 Pt 1):1141-5.
Score: 0.034
-
Long-term survival in phase II trials of gemcitabine plus cisplatin for advanced transitional cell cancer. Urol Oncol. 2002 Jul-Aug; 7(4):153-7.
Score: 0.031
-
Patient-Reported Outcomes from the Phase III Randomized IMmotion151 Trial: Atezolizumab + Bevacizumab versus Sunitinib in Treatment-Naïve Metastatic Renal Cell Carcinoma. Clin Cancer Res. 2020 06 01; 26(11):2506-2514.
Score: 0.027
-
Prognostic importance of lymphovascular invasion in urothelial carcinoma of the renal pelvis. Cancer. 2018 06 15; 124(12):2507-2514.
Score: 0.023
-
Bevacizumab alone or in combination with TRC105 for patients with refractory metastatic renal cell cancer. Cancer. 2017 Dec 01; 123(23):4566-4573.
Score: 0.022
-
Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial. Lancet Oncol. 2016 Mar; 17(3):378-388.
Score: 0.020
-
Variability in surgical quality in a phase III clinical trial of radical cystectomy in patients with organ-confined, node-negative urothelial carcinoma of the bladder. J Surg Oncol. 2015 Jun; 111(7):923-8.
Score: 0.019
-
Doxorubicin plus the IGF-1R antibody cixutumumab in soft tissue sarcoma: a phase I study using the TITE-CRM model. Ann Oncol. 2015 07; 26(7):1459-64.
Score: 0.019
-
Significance of lymphovascular invasion in organ-confined, node-negative urothelial cancer of the bladder: data from the prospective p53-MVAC trial. BJU Int. 2015 Jul; 116(1):44-9.
Score: 0.019
-
Stereotactic body radiotherapy for the treatment of oligometastatic renal cell carcinoma. Am J Clin Oncol. 2013 Dec; 36(6):589-95.
Score: 0.017
-
The effect of prior androgen synthesis inhibition on outcomes of subsequent therapy with docetaxel in patients with metastatic castrate-resistant prostate cancer: results from a retrospective analysis of a randomized phase 3 clinical trial (CALGB 90401) (Alliance). Cancer. 2013 Oct 15; 119(20):3636-43.
Score: 0.017
-
Dose-escalated radiotherapy for high-risk prostate cancer: outcomes in modern era with short-term androgen deprivation therapy. Int J Radiat Oncol Biol Phys. 2010 May 01; 77(1):125-30.
Score: 0.013
-
[Changes in the treatment of urogenital tuberculosis]. Wien Klin Wochenschr. 1988 Sep 09; 100(17):573-6.
Score: 0.012
-
Long-term follow-up of nonmyeloablative allogeneic stem cell transplantation for renal cell carcinoma: The University of Chicago Experience. Bone Marrow Transplant. 2005 Feb; 35(3):253-60.
Score: 0.009
-
Use of a new tumor marker, urinary NMP22, in the detection of occult or rapidly recurring transitional cell carcinoma of the urinary tract following surgical treatment. J Urol. 1996 Aug; 156(2 Pt 1):363-7.
Score: 0.005